The prognostic significance of high/positive expression of cyclin B1 in patients with three common digestive cancers: a systematic review and meta-analysis

Yong Wen, Lei Cao, Wen-Ping Lian and Guo-Xia Li _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:96373-96383. https://doi.org/10.18632/oncotarget.21273

Metrics: PDF 1126 views  |   HTML 1487 views  |   ?  


Yong Wen1,*, Lei Cao2,*, Wen-Ping Lian3 and Guo-Xia Li4

1Chinese Medicine Department, Southwest Medical University Affiliated Hospital, Luzhou 646000, China

2Department of Pediatrics, Gansu Provincial Maternity and Child Care Hospital, Lanzhou 730000, China

3Department of Clinical Laboratory, The Third People’s Hospital of He’nan Province, Zhengzhou 450000, China

4Department of Pathology, Shanghai Minhang District Central Hospital, Shanghai 201199, China

*These authors contributed equally to this work

Correspondence to:

Guo-Xia Li, email: [email protected]

Keywords: cyclin B1, gastric cancer, colorectal cancer, esophageal cancer, prognosis

Received: February 08, 2017     Accepted: September 08, 2017     Published: September 26, 2017


Recently, several studies have reported that the expression of cyclin B1 may be associated with the prognosis of cancer. Nevertheless, their conclusions were still controversial. The present was designed to analyze and evaluate the prognostic role of cyclin B1 expression in patients with digestive cancer. PubMed, Embase, Cochrane Library and Web of Science were searched to January, 2017. Pooled odds ratio (OR) with 95% confidence intervals (CIs) were estimated. For the pooled OR estimates of OS, we performed subgroup analysis. Besides, sensitivity analysis was performed to examine the stability of the combined results. All statistical analyses were performed using standard statistical procedures provided in RevMan 5.2. A total of 12 studies (N = 2080 participants) were included for this meta-analysis. The positive/high expression of cyclin B1 had an obvious association with both 3-year overall survival (OR 0.21, 95% CI 0.12–0.37; P < 0.00001) and 5-year overall survival (OR 0.20, 95% CI 0.12–0.34; P < 0.00001) in esophageal cancer, and 5-year overall survival of colorectal cancer (OR 2.01, 95% CI 1.32–3.08; P = 0.001). This meta-analysis indicated that positive/high expression of cyclin B1 may have a close association with worse survival in patients with esophageal cancer, but better prognosis in patients with colorectal cancer.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21273